Including the Wall Street Journal?
Anyway, enough quoting me. Enjoy the ride.
Did you read the WSJ article? If so, what were your impressions?
I've said before you can interpret CYDY activities from whatever predisposition you have about it.
I read the article once, someone on another board ignored the pay wall it was behind.
My impression of the article was that it was announced as a generalization of the excitement/rush of so many companies to develop co-vid meds but turned into a focused hit piece on one company. So thought it was misleading.
One of the things mentioned in the article were NPs exaggerations regarding timelines and promise of the drug. Well yes most everything has taken longer than thought. But it has happened (BLA filed, Financing obtained, mfging and distribution agreements, application for uplisting, initiation of trials (cancer, m/m co-vid completed). Is LL a knockout homerun drug? We do not know that yet (cancer results were excellent) but will know soon about co0vid. Also, I am continually advised that biotech derug development takes time and there are delays. But I do have the impression that NP is not always realistic about timelines.
Additionally, all data to date says LL is a safe drug.
The WSJ also focused on NP going off on staff when challenged about exaggerated timelines. Cant say this didn't happen, cant say it did. Wouldn't be surprised if it did. The article seems to use previous disgruntled staff as sources.
The WSJ seemed to me to distort deaths that I think were related to the early Montefiore study for c/s but that's an area I'm not confident about in my understanding.
WSJ mentioned that CYDY was denied the BLA for HIV because of using mock data. This looks real bad, it sounded like it was a permanent denial as opposed to the need to just include more data that was missing. WSJ later printed a retraction suggesting they had done a thorough review of the company.
Also WSJ hit on NP's stock sale and quoted him as saying he was entitled to have some security or some such thing. Now NP has said he sold stock to protect the stock and secure mfg. Now this is a strange situation and I really do not know what to believe about this. So I have some doubt.
The WSJ mentioned other things I do not recall and therefore can not discuss.
My conclusion is that somebody birddogged WSJ onto CYDY. Unless CYDY is such huge charlatan of a company that everyone in the industry believes is fake. I do not think that is the case based on cancer trials, safety data, number of doctors and institutions involved.
Just trying to explain how I look at things.